<DOC>
	<DOCNO>NCT02475317</DOCNO>
	<brief_summary>The purpose study assess relative potency multiple oral dos LUM001 SHP626 administer 7 day assess fecal bile acid excretion overweight obese adult subject . This study design address relative potency question first time .</brief_summary>
	<brief_title>Study Assess Relative Potency Multiple Oral Doses LUM001 SHP626 Overweight Obese Adults Assessed Fecal Bile Acid Excretion</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Bile Acids Salts</mesh_term>
	<criteria>1 . An understanding , ability , willingness fully comply study procedure , study diet , restriction . 2 . Ability voluntarily provide write , sign , date ( personally via legallyauthorized representative ) inform consent/and assent applicable participate study . 3 . Aged 1865 year inclusive time consent . The date signature inform consent define begin screen period . This inclusion criterion assess first screen visit . 4 . Males agree comply applicable contraceptive requirement protocol female nonchildbearing potential ( see Section 4.4 detail ) . 5 . Must consider generally healthy . Health status define absence evidence active chronic disease ( see Section 7.2.2.1 detail exception ) follow completion detail medical surgical history , complete physical examination , vital sign , 12lead ECG , hematology , blood chemistry , urinalysis . 6 . Must body mass index 25.035.0 kg/mÂ² inclusive body weight &gt; 63.5 kg ( 140 lb first screen visit ) . This inclusion criterion assess first screen visit . 7 . All clinical laboratory parameter within normal laboratory limit find clinically significant principal investigator . 8 . Ability swallow dose ( ) investigational product ( ) . 1 . History hematological , hepatic , respiratory , cardiovascular , renal , neurological , psychiatric disease , gall bladder removal , current recurrent disease could affect action , absorption , disposition investigational product , clinical laboratory assessment . 2 . Current relevant history physical psychiatric illness , medical disorder may require treatment make subject unlikely fully complete study , condition present undue risk investigational product procedure . 3 . Known suspected intolerance hypersensitivity investigational product ( ) , closelyrelated compound , state ingredient . 4 . Significant illness , judge investigator , within 2 week prior first dose investigational product . 5 . Known history alcohol substance abuse within last year . 6 . Donation blood blood product ( eg , plasma platelet ) within 60 day prior receive first dose investigational product . 7 . Within 30 day prior first dose investigational product : Have use investigational product ( elimination halflife &lt; 6 day , otherwise 5 halflives ) . Have enrol clinical study ( include vaccine study ) , investigator 's opinion , may impact Shiresponsored study . Have substantial change eat habit exercise routine , assess investigator 8 . Confirmed rest systolic blood pressure &gt; 145 mmHg &lt; 89 mmHg , diastolic blood pressure &gt; 95 mmHg &lt; 59 mmHg . 9 . Twelvelead ECG demonstrate QTc &gt; 460 millisecond male subject &gt; 470 millisecond female subject screen . If QTc exceed 460 millisecond male 470 millisecond female , ECG repeat 2 time average 3 QTc value use determine subject 's eligibility 10 . A positive screen drug abuse screen Day 3 ( checkin ) . 11 . Male subject consume 21 unit alcohol per week 3 unit per day . Female subject consume 14 unit alcohol per week 2 unit per day . ( 1 alcohol unit=1 beer 1 wine [ 5 oz/150 mL ] 1 liquor [ 1.5 oz/40 mL ] 0.75 oz alcohol ) . 12 . A positive HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody screen . 13 . Use tobacco ( eg , smoke chew ) nicotinecontaining product ( eg , gum , patch ) form . Exusers must report stop use tobacco least 30 day prior receive first dose investigational product . 14 . Routine consumption 2 unit caffeine per day subject experience caffeine withdrawal headache . ( One caffeine unit contain follow item : one 6 oz [ 180 mL ] cup coffee , two 12 oz [ 360 mL ] can cola , one 12 oz cup tea , three 1 oz [ 85 g ] chocolate bar . Decaffeinated coffee , tea , cola consider contain caffeine . ) 15 . Prior screen failure , randomization , participation , enrollment study . If subject successfully complete study use LUM001 SHP626 , may participate study provide least 30 day pass since last dose investigational product successfully complete screening procedure 16 . Current use medication ( include overthecounter , herbal , homeopathic preparation ) exception medication list Section 5.2.1 . ( Current use define use within 14 day first dose investigational product . ) 17 . An inability follow standardize diet meal schedule inability fast , require study . 18 . Colonoscopy , barium enema , test require bowel cleansing within 4 week prior first dose investigational product . 19 . Subjects report typically less 3 bowel movement per week great 3 bowel movement per day . 20 . Use antibiotic within 30 day prior first dose investigational product . 21 . Use bile acid sequestrants within 30 day prior first dose investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Volunteer</keyword>
</DOC>